Resources Repository
-
ArticlePublication 2018Motivational Interviewing: A Promising Tool to Address Vaccine Hesitancy
In most countries, there is an increase in ‘‘vaccine hesitancy,” defined as the proportion of …
In most countries, there is an increase in ‘‘vaccine hesitancy,” defined as the proportion of parents who refuse some, many, or all vaccines or who adopt a delayed vaccination schedule, regardless of the availability of vaccination services. Generally, approaches to address vaccine hesitancy suggest either strong policies of mandatory immunization or more traditional approaches of education and information. Although mandatory immunization policies may increase uptake of vaccines, they do not address the root causes of…
Government/Law | Infectious Diseases | Preferences/Values | Social Determinants | Culture/Society | Health/Medicine | Science/Technology | North America -
ArticlePublication 2021Anti-Vaccination Infodemic on Social Media: A Behavioral Analysis
Vaccinations are without doubt one of the greatest achievements of modern medicine, and there is …
Vaccinations are without doubt one of the greatest achievements of modern medicine, and there is hope that they can constitute a solution to halt the ongoing COVID-19 pandemic. However, the anti-vaccination movement is currently on the rise, spreading online misinformation about vaccine safety and causing a worrying reduction in vaccination rates worldwide. In this historical time, it is imperative to understand the reasons of vaccine hesitancy, and to find effective strategies to dismantle the rhetoric…
Government/Law | Infectious Diseases | Preferences/Values | Social Determinants | Culture/Society | Health/Medicine | Science/Technology | North America -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Government/Law | Infectious Diseases | Probability/Bayes | Test Performance | Technology Assessment | Health Systems | Policy/Regulation | Health/Medicine | Global | North America -
ArticlePublication 2019Cost-Effectiveness of Latent TB Screening before Immigration to Low-Incidence Countries
Despite prospective migrants to countries where the incidence of TB is low receiving TB screening …
Despite prospective migrants to countries where the incidence of TB is low receiving TB screening for active infections, screening for latent TB infection before immigration is rare. The authors used discrete event simulation to evaluate the cost-effectiveness preimmigration latent TB infection screening for migrants to low-incidence countries. They calculated cost per quality-adjusted life-year gained for migrants from countries with different TB incidences. Their analysis when combined with research on sustainability, acceptability, and program implementation can…
Cost-Effectiveness Analysis | Government/Law | Infectious Diseases | Mathematical Models | Dynamic Simulation | Health/Medicine | Global -
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Cost-Effectiveness Analysis | Government/Law | Infectious Diseases | Costing Methods | Health Outcomes | Evidence Synthesis | Benefit-Cost Analysis | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Global Governance | Economics/Finance | Health/Medicine | Science/Technology | Global -
DataWeb Portal 2024Healthcare Cost and Utilization Project (HCUP)
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in …
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in the United States, including information on in-patient care, ambulatory care, and emergency department visits. HCUP enables researchers, insurers, policymakers and others to study health care delivery and patient outcomes over time, and at the national, regional, State, and community levels. The Agency for Healthcare Research and Quality (AHRQ) provides a range of data resources in the form of online, searchable…
Cost-Effectiveness Analysis | Government/Law | Infectious Diseases | Costing Methods | Health Outcomes | Evidence Synthesis | Test Performance | Technology Assessment | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Science/Technology | North America -
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Cost-Effectiveness Analysis | Government/Law | Infectious Diseases | Costing Methods | Health Outcomes | Test Performance | Decision Analysis | Technology Assessment | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | Science/Technology | North America -
ArticlePublication 2016What Determines HIV Prevention Costs at Scale?
Human immunodeficiency virus (HIV) prevention services for key populations are commonly delivered through NGOs. However, …
Human immunodeficiency virus (HIV) prevention services for key populations are commonly delivered through NGOs. However, funding for HIV prevention remains scarce, and there are growing calls internationally to improve the efficiency of HIV prevention programmes as a key strategy to reach global HIV targets. To date, there is limited evidence on the determinants of costs of HIV prevention delivered through NGOs, and thus, policymakers have little guidance in how best to design programmes that are…
Cost-Effectiveness Analysis | Government/Law | Infectious Diseases | Costing Methods | Health Systems | Global Governance | Economics/Finance | Health/Medicine | Asia & Pacific